Isbn: 9789535125860 - myelodysplastic syndromes (13 resultados)

Condición: New.

Condición: New.

Condición: As New. Unread book in perfect condition.

Condición: New. In.

Condición: New.

Condición: As New. Unread book in perfect condition.

HRD. Condición: New. New Book. Shipped from UK. THIS BOOK IS PRINTED ON DEMAND. Established seller since 2000.

HRD. Condición: New. New Book. Delivered from our UK warehouse in 4 to 14 business days. THIS BOOK IS PRINTED ON DEMAND. Established seller since 2000.

Gebunden. Condición: New. Dieser Artikel ist ein Print on Demand Artikel und wird nach Ihrer Bestellung fuer Sie gedruckt. KlappentextrnrnThis book is a comprehensive overview of myelodysplastic syndromes (MDS). MDS are a heterogeneous group of clonal hematopoietic stem cell disorders characterized by ineffective hematopoiesis, peripheral cytopenias, frequent karyot.…

Buch. Condición: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -This book is a comprehensive overview of myelodysplastic syndromes (MDS). MDS are a heterogeneous group of clonal hematopoietic stem cell disorders characterized by ineffective hematopoiesis, peripheral cytopenias, frequent karyotypic abnormalities, and risk of transformation to acute myeloid leukemia (AML). Median age of patients with MDS is about 70 years. Various immune abnormalities occur in MDS patients, and the relationship between autoimmune disorders and MDS is described. Accurate prognostication and risk stratification for individual patients with MDS are important for clinical treatment decisions. Patients with MDS are classified into two broad prognostic categories: lower risk and higher risk. The approval of lenalidomide, azacitidine, and decitabine in last 10 years helped to diminish the clinical impact of MDS and delayed its progression to AML. 210 pp. Englisch.…

Buch. Condición: Neu. Myelodysplastic Syndromes | Ota Fuchs | Buch | 210 S. | Englisch | 2016 | IntechOpen | EAN 9789535125860 | Verantwortliche Person für die EU: BoD - Books on Demand, In de Tarpen 42, 22848 Norderstedt, info[at]bod[dot]de | Anbieter: preigu Print on Demand.

Buch. Condición: Neu. This item is printed on demand - Print on Demand Titel. Neuware -This book is a comprehensive overview of myelodysplastic syndromes (MDS). MDS are a heterogeneous group of clonal hematopoietic stem cell disorders characterized by ineffective hematopoiesis, peripheral cytopenias, frequent karyotypic abnormalities, and risk of transformation to acute myeloid leukemia (AML). Median age of patients with MDS is about 70 years. Various immune abnormalities occur in MDS patients, and the relationship between autoimmune disorders and MDS is described. Accurate prognostication and risk stratification for individual patients with MDS are important for clinical treatment decisions. Patients with MDS are classified into two broad prognostic categories: lower risk and higher risk. The approval of lenalidomide, azacitidine, and decitabine in last 10 years helped to diminish the clinical impact of MDS and delayed its progression to AML.Books on Demand GmbH, Überseering 33, 22297 Hamburg 210 pp. Englisch.…

Buch. Condición: Neu. nach der Bestellung gedruckt Neuware - Printed after ordering - This book is a comprehensive overview of myelodysplastic syndromes (MDS). MDS are a heterogeneous group of clonal hematopoietic stem cell disorders characterized by ineffective hematopoiesis, peripheral cytopenias, frequent karyotypic abnormalities, and risk of transformation to acute myeloid leukemia (AML). Median age of patients with MDS is about 70 years. Various immune abnormalities occur in MDS patients, and the relationship between autoimmune disorders and MDS is described. Accurate prognostication and risk stratification for individual patients with MDS are important for clinical treatment decisions. Patients with MDS are classified into two broad prognostic categories: lower risk and higher risk. The approval of lenalidomide, azacitidine, and decitabine in last 10 years helped to diminish the clinical impact of MDS and delayed its progression to AML. …